Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 325 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Respiratory Distress Syndrome, Adult Clear all
Completed Phase 3 Interventional Results available

Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing

NCT00626028
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Interventions
Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Stanford, California • Denver, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 14, 2026, 9:59 PM EDT
Recruiting Not applicable Interventional

Vascular ARDS Recruitment After Inhaled Nitric Oxide

NCT05801224
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Ventilation Perfusion Mismatch
Interventions
Nitric Oxide
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 9:59 PM EDT
Terminated No phase listed Observational

Low-Level Laser Therapy Treatment of Lung Inflammation in Post-COVID-19 Recovery

NCT05258617
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome
Interventions
LLLT Photobiomodulation
Device
Lead sponsor
Ward Photonics LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Berkeley, California • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 14, 2026, 9:59 PM EDT
Suspended Phase 2 Interventional

Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial

NCT07123961
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Ventilator Management, Lung-protective Ventilation, Pediatric Acute Respiratory Distress Syndrome (PARDS)
Interventions
High Driving Pressure Mechanical Ventilation, Low Driving Pressure Mechanical Ventilation
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Weeks to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 3 Interventional

Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

NCT00000579
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Lung Diseases
Interventions
Low Tidal Volume Ventilation, Positive End-Expiratory Pressure, Lysofylline, Methylprednisolone, Ketoconazole, Fluid Management, Pulmonary Artery Catheter
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
20
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 14, 2026, 9:59 PM EDT
Terminated Not applicable Interventional

Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients

NCT03202641
View directory record Official record
Conditions
ARDS, Human, Lung Injury, Acute, Respiratory Distress Syndrome, Mechanical Ventilation Complication, Alveolar Edema, Right Heart Failure, Right Ventricular Dysfunction
Interventions
PEEP ARDSnet, PEEP LRM
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 14, 2026, 9:59 PM EDT
Recruiting No phase listed Observational

The APS Phenotyping Study

NCT06521502
View directory record Official record
Conditions
ARDS, Sepsis, Pneumonia
Interventions
Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan
Other · Procedure · Radiation
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 14, 2026, 9:59 PM EDT
No Longer Available No phase listed Expanded access

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

NCT04355494
View directory record Official record
Conditions
COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Results available

Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)

NCT04530604
View directory record Official record
Conditions
COVID, Sars-CoV2, COVID-19, Acute Respiratory Distress Syndrome
Interventions
Defibrotide
Drug
Lead sponsor
Gregory Yanik
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 14, 2026, 9:59 PM EDT
Active, not recruiting No phase listed Observational

Post Acute Sequelae of COVID-19

NCT04964115
View directory record Official record
Conditions
Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
Interventions
Cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 4 Interventional Results available

Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management

NCT01710891
View directory record Official record
Conditions
Acute Respiratory Distress
Interventions
CMAC videolaryngoscope, Direct Laryngoscopy
Procedure
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 14, 2026, 9:59 PM EDT
Active, not recruiting No phase listed Observational

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

NCT05388708
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Interventions
ECMO support, PROSpect protocolized therapies
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
14 Days to 20 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 14, 2026, 9:59 PM EDT
Terminated Phase 2 Interventional Results available

Study of Varespladib in Patients Hospitalized With Severe COVID-19

NCT04969991
View directory record Official record
Conditions
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Varespladib, Placebo
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Ventura, California • Miami, Florida • Munster, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Losartan for Patients With COVID-19 Requiring Hospitalization

NCT04312009
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

NCT04388826
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Veru-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Scottsdale, Arizona • Saint Louis Park, Minnesota • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 14, 2026, 9:59 PM EDT
Terminated Phase 2 Interventional Results available

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

NCT04351243
View directory record Official record
Conditions
COVID-19
Interventions
Gimsilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 14, 2026, 9:59 PM EDT
Withdrawn Phase 1 Interventional

Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome

NCT04737161
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Covid19
Interventions
T regulatory cells
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 14, 2026, 9:59 PM EDT
Not listed Not applicable Interventional

Clinical Decision Support for Mechanical Ventilation of Patients With ARDS

NCT03984175
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Implementation of Processes
Procedure
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 14, 2026, 9:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

NCT04357782
View directory record Official record
Conditions
COVID-19, Hypoxia
Interventions
L-ascorbic acid
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 14, 2026, 9:59 PM EDT
Not listed No phase listed Observational

Description of Fluid Balance in Patients With Acute Respiratory Failure

NCT02523872
View directory record Official record
Conditions
Respiratory Insufficiency
Interventions
Not listed
Lead sponsor
Smiths Medical, ASD, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2015 · Synced Oct 14, 2026, 9:59 PM EDT
Terminated Phase 1 Interventional Results available

Study of Descartes-30 in Acute Respiratory Distress Syndrome

NCT04524962
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Covid19
Interventions
Descartes 30
Biological
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Iowa City, Iowa • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 14, 2026, 9:59 PM EDT
Not listed Phase 2 Interventional

Trial of Steroids in Pediatric Acute Lung Injury/ARDS

NCT01274260
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Acute Lung Injury (ALI)
Interventions
methylprednisolone, Normal Saline (0.9%)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 14, 2026, 9:59 PM EDT